GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genus PLC (FRA:GBE) » Definitions » ROCE %
中文

Genus (FRA:GBE) ROCE % : 5.55% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

Genus ROCE % Definition

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genus's annualized ROCE % for the quarter that ended in Dec. 2023 was 5.55%.


Genus ROCE % Historical Data

The historical data trend for Genus's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genus ROCE % Chart

Genus Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.08 7.20 8.61 6.87 6.22

Genus Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.36 6.70 4.66 7.61 5.55

Genus ROCE % Calculation

Genus's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=62.582/( ( (1185.879 - 176.268) + (1174.145 - 171.547) )/ 2 )
=62.582/( (1009.611+1002.598)/ 2 )
=62.582/1006.1045
=6.22 %

Genus's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=57.574/( ( (1174.145 - 171.547) + (1223.324 - 149.622) )/ 2 )
=57.574/( ( 1002.598 + 1073.702 )/ 2 )
=57.574/1038.15
=5.55 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genus  (FRA:GBE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Genus ROCE % Related Terms

Thank you for viewing the detailed overview of Genus's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genus (FRA:GBE) Business Description

Traded in Other Exchanges
Address
Matrix House, Basing View, Basingstoke, Hants, GBR, RG21 4DZ
Genus PLC is a biotechnology company that develops animal genetics for agricultural purposes. The company breeds and distributes the genes of pigs and bulls, scientifically selecting livestock whose offspring are designed to increase the profitability of its customers. In the porcine market, Genus sells boars and sows that produce offspring with desirable characteristics, such as feed-efficient growth or leaner meat. In the dairy and beef markets, the company's primary product is bull semen, which is delivered through artificial insemination to improve its customers' herds and their efficiency. Genus also offers embryos through its subsidiary IVB.

Genus (FRA:GBE) Headlines

No Headlines